Abstract:Shiyang Wang, Binhe Tian, Hanping Wang Division of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, People's Republic of China Correspondence: Hanping Wang, Division of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuaifuyuan, Dongcheng District, Beijing, 100730, People's Republic of China, Tel +86010-69158760, Email Objective: This study aimed to investigate the risk factors for immune checkpoint inhibitor (ICI)-related colitis and its impact on prognosis in the treatment of lung cancer. Methods: This retrospective, single-center, observational study included lung cancer patients who received ICIs treatment between January 2016 and January 2022. The correlation between immune-related colitis and prognosis was evaluated. Kaplan-Meier analysis was used to compare the median overall survival (OS). Results: Among the lung cancer patients treated with ICIs, the incidence of colitis was 5.88% (35/595). The severity of colitis was graded as follows: grade 1 (8 cases), grade 2 (15 cases), grade 3 (9 cases), and grade 4 (3 cases). Except for the 1 case that resulted in death due to grade 4 adverse events, the remaining patients showed significant improvement after corticosteroid intervention. Among the 35 patients with ICI-related colitis, complete remission was not achieved. Partial remission was observed in 11 cases, disease stability in 16 cases, disease progression in 7 cases, and death in 1 case. Among the included patients, 19 chose to continue ICI treatment after symptom relief. The overall survival for all participants was 34 months (IQR: 24– 36), while the overall survival for those who received ICI treatment again was 36 months (IQR: 32-NA), and for those who did not receive ICI treatment again was 32 months (IQR: 21– 35). Kaplan-Meier survival curve analysis showed that patients who received ICI treatment again had significantly better overall survival compared to other patients. Conclusion: Immune-related colitis remains a significant concern in lung cancer patients treated with ICIs and requires close monitoring and timely intervention. Restarting treatment after symptom relief can provide additional benefits for patients. Keywords: lung cancer, immune checkpoint inhibitors, colitis, risk factors, prognosis Lung cancer is a prevalent malignancy characterized by its high invasiveness and metastatic potential. Conventional treatments, such as surgical resection, radiation therapy, and chemotherapy, have limited efficacy and often entail significant adverse effects. 1 Non-small cell lung cancer (NSCLC) represents the most common subtype, with over 50% of patients being diagnosed at an advanced stage and a dismal 5-year survival rate of merely 5%. 2 Standard therapies, including chemotherapy and radiation, typically yield moderate responses in patients with metastatic NSCLC, with 5-year survival rates ranging from 6% to 30%. 3 Immune checkpoint inhibitors (ICIs) have emerged as a novel class of antineoplastic agents, harnessing the immune system to combat tumor cells by inhibiting immune checkpoint molecules—negative regulators found on the surface of T cells that hamper their activation and proliferation. 4 In recent years, the advent of ICIs has revolutionized the prognosis of various malignancies. Monoclonal antibodies targeting programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have demonstrated remarkable antitumor activity by selectively activating T cells and suppressing the immune system. 5 Notably, the KEYNOTE-021 study revealed that the combination of chemotherapy and pembrolizumab achieved an impressive efficacy rate of 55% in treating NSCLC, significantly surpassing the 29% observed in the chemotherapy-alone arm, while simultaneously reducing the risk of disease progression by 47%. 6 The employment of ICIs has revolutionized the survival outcomes of NSCLC patients, exhibiting a more favorable toxicity profile compared to traditional chemotherapy. 7 Nevertheless, ICIs may also elicit immune-related adverse events (irAEs), including gastrointestinal symptoms such as abdominal pain, diarrhea, hematochezia, nausea, and vomiting. Severe cases may manifest with fever, dehydration, electrolyte imbalances, and other life-threatening complications. Although the incidence of organ-specific irAEs remains relatively low, the utilizatio -Abstract Truncated-

Pan‐Cancer Survival Impact of Immune Checkpoint Inhibitors in a National Healthcare System

Immune Checkpoint Inhibitors and Survival Outcomes in Brain Metastasis: A Time Series-Based Meta-Analysis

Clinical Outcomes of Immune Checkpoint Inhibitors in Unique Cohorts Underrepresented in Clinical Trials

Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors

Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium

The landscape of checkpoint inhibitors in oncology

The real-world insights on the use, safety, and outcome of immune-checkpoint inhibitors in underrepresented populations with lung cancer

Immune Checkpoint Inhibitor Increased Mortality in Lung Cancer Patients with Pneumocystis Jirovecii Pneumonia: a Comparative Retrospective Cohort Study

Checkpoint based immunotherapy in non-small cell lung cancer: a real-world retrospective study

Real-World Outcomes and Prognostic Factors among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors As First-Line Therapy

The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real‐world, multicenter, retrospective study

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis

Impact of performance status on survival outcomes and health care utilization in patients with advanced non–small cell lung cancer treated with immune checkpoint inhibitors.

Outcomes with initiation of inpatient immunotherapy.

Inpatient and ED Use Among Melanoma and Lung Cancer Patients Receiving Immune Checkpoint Inhibitors (GP133)

Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy

Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer.

Association of immune checkpoint inhibitor introduction and changes in survival disparities by health insurance coverage among individuals newly diagnosed with advanced cancers in the US.

Incidence of checkpoint inhibitor-associated inflammatory arthritis, immunomodulation and mortality in cancer patients on immunotherapy: a retrospective cohort study

Risk Factors and Prognostic Analysis of Immune Checkpoint Inhibitor-Related Colitis in Lung Cancer

Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis